Search

Your search keyword '"Assaad, Souad"' showing total 2 results
Start Over Author "Assaad, Souad" Topic nivolumab
2 results on '"Assaad, Souad"'

1. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up

Author

Levy, Manon, Abeillon, Juliette, Dalle, Stéphane, Assaad, Souad, Borson-Chazot, Françoise, Disse, Emmanuel, Raverot, Gérald, Cugnet-Anceau, Christine, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Subjects
nivolumab, programmed cell death 1 protein, lcsh:R, programmed cell death 1 ligand 1 protein, lcsh:Medicine, immunotherapy, pembrolizumab, adrenal insufficiency, Article, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, hypophysitis
Abstract

International audience; Hypophysitis, secondary to programmed cell death 1 protein (PD1) and programmed cell death 1 ligand 1 (PDL1) inhibitors, were thought to be rare, with only a few studies describing more than one case with long-term follow-up. The aim of the present study was to describe the clinical, laboratory, and morphological characteristics of PD1/PDL1 inhibitor-induced hypophysitis, and its long-term course. This cohort study was conducted at the University Hospital of Lyon, France, with longitudinal follow-up of patients. Seventeen cases of PD1/PDL1 inhibitor-induced hypophysitis were included. The median time to onset of hypophysitis was 28 weeks (range: 10-46). At diagnosis, 16 patients complained of fatigue, 12 of nausea or loss of appetite, while headache was rare. We found no imaging pituitary abnormality. All patients presented adrenocorticotropic hormone (ACTH) deficiency; other pituitary deficiencies were less common (n = 7). At last follow-up (median: 13 months), ACTH deficiency persisted in all but one patient and one patient recovered from gonadotropic deficiency. PD1/PDL1 inhibitor-induced hypophysitis is a clinical entity different from those associated to cytotoxic T-lymphocyte antigen-4 (CTLA4) inhibitors, with less obvious clinical and radiological signs, and probably a different mechanism. The paucity of symptoms demonstrates the need for systematic hormonal follow-up for patients receiving PD1/PDL1 inhibitors.

Published
2020
Full Text
View/download PDF

2. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.

Author

Catozzi, Simona, Assaad, Souad, Delrieu, Lidia, Favier, Bertrand, Dumas, Elise, Hamy, Anne-Sophie, Latouche, Aurélien, Crochet, Hugo, Blay, Jean-Yves, Mullaert, Jimmy, Ballesta, Annabelle, and Heudel, Pierre

Subjects
*LUNG cancer, *IMMUNE checkpoint inhibitors, *INTRAVENOUS therapy, *CANCER chemotherapy, *METASTASIS, *RETROSPECTIVE studies, *MONOCLONAL antibodies, *ANTINEOPLASTIC agents, *SEX distribution, *RISK assessment, *TREATMENT effectiveness, *SURVIVAL analysis (Biometry), *NIVOLUMAB, *DESCRIPTIVE statistics, *CLINICAL chronobiology, *ODDS ratio, *DRUG toxicity, *LONGITUDINAL method, MORTALITY risk factors
Abstract

Recent retrospective studies suggest potential large patient's benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment timing and patient survival, neoplastic response and toxicities was investigated, together with interactions with performance status (PS) and sex. A cohort of patients with metastatic or locally advanced solid tumors, who received pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab, alone or with concomitant chemotherapy, between November 2015 and March 2021, at the Centre Leon Bérard (France), was retrospectively studied. 361 patients were investigated (80% non-small cell lung cancer patients, mean [SD] age: 63 [11] years, 39% of women, 83% PS0–1 at first infusion, 19% received concomitant chemotherapy). ICB were administered from 07:25 to 17:21 and optimal morning/afternoon cut-off was 11:37. Morning infusions were associated with increased OS as compared to afternoon (median 30.3 vs 15.9 months, p = 0.0024; HR 1.56 [1.17-2.1], p = 0.003). A strong PS-timing interaction was found (PS0-1 patients, HR=1.53 [1.10-2.12], p = 0.011; PS2–3 patients, HR=0.50 [0.25–0.97], p = 0.042). Morning PS0–1 patients displayed increased OS (median 36.7 vs 21.3 months, p = 0.023), partial/complete response rate (58% vs 41%, p = 0.027), and grade1–3 toxicities (49% vs 34%, p = 0.028). Mortality risk ratio between infusions at worst time-of-day, estimated at 13:36 [12:48–14:23], and in early morning was equal to 4.8 ([2.3-10.1], p = 0.008). Timing differences in toxicities resulted significant only in female patients (women vs men: p < 0.001 vs 0.4). Early morning ICB infusion was associated with increased OS, response, and toxicities in patients with PS0–1 as compared to later infusions within the day. Prospective randomized trials are needed to confirm this retrospective study. • Early morning Immune Checkpoint Blockade (ICB) was associated with increased survival and response. • All ICB timing differences were observed in patients with PS0-1 but not with PS2-3. • Best vs Worst ICB timing resulted in a-4.8-fold difference in patient mortality risk. • ICB toxicities were highly timing-dependent in women and not in men. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results